Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly Cardiometabolic Health.Courtesy Eli Lilly; Getty Images; BI Illustration Eli Lilly makes the popular shots ...

Still, it requires a special injector pen and consistent refrigeration. Patients also reported uncomfortable side effects from Ozempic, like nausea, vomiting, and diarrhea. Eli Lilly hopes that a ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition ... which is available in vial form or as a disposable pen. Sanofi fights back This represents Sanofi's first foray into ...

Like Eli Lilly and Sanofi, Novo Nordisk has agreed to implement a texting system to assist pharmacists and patients to determine eligibility for low-cost insulin, and alert patients about this low ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...